Jason Stein
Gründer bei Actin Biomed LLC
Profil
Dr. Jason Stein is Partner at Actin Capital LLC and Co-Founder & Co-Chairman at Actin Biomed LLC.
He is on the Board of Directors at Cutanea Life Sciences, Inc.
Prior to co-founding Actin Biomed in December 2006, Dr. Stein was a Senior Analyst at Paramount BioCapital Asset Management, Inc. and also served on the board at Chelsea Therapeutics International Ltd., Velcera, Inc., and Ivory Capital Corp.
Dr. Stein received his undergraduate degree from the University of Michigan and an MD from the Saba University School of Medicine BV.
Aktive Positionen von Jason Stein
| Unternehmen | Position | Beginn |
|---|---|---|
| Actin Capital LLC | Corporate Officer/Principal | 01.12.2006 |
Cutanea Life Sciences, Inc.
 Cutanea Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology Cutanea Life Sciences, Inc. Develops and commercialises innovative dermatology related products. The company was founded in May 2005 and is headquartered in Wayne, PA. | Direktor/Vorstandsmitglied | 01.06.2004 |
Actin Biomed LLC
 Actin Biomed LLC Investment ManagersFinance Founded in 2006 by Michael Weiser and Jason Stein, Actin Biomed LLC is a venture capital firm located in New York City. | Gründer | 21.07.2011 |
Ehemalige bekannte Positionen von Jason Stein
| Unternehmen | Position | Ende |
|---|---|---|
| CHELSEA THERAPEUTICS INTERNATIONAL LTD. | Direktor/Vorstandsmitglied | 08.02.2008 |
| Ivory Capital Corp. | Direktor/Vorstandsmitglied | 02.08.2005 |
Foresight Biotherapeutics, Inc.
 Foresight Biotherapeutics, Inc. BiotechnologyHealth Technology Foresight Biotherapeutics, Inc. develops drugs and therapies for diseases of the eyes and ears. It offers FST-100 (topical ophthalmic drops combining povidone iodine and dexamethasone), a therapy in late-stage development for the treatment of infectious conjunctivitis, an ocular surface condition commonly referred to as pink eye. The company was founded by Jason Stein and Michael Weiser on September 4, 2008 and is headquartered in New York, NY. | Gründer | - |
Velcera LLC
 Velcera LLC Pharmaceuticals: MajorHealth Technology Velcera LLC operates as a pharmaceutical company. It focuses on innovation in the expanding pet health market and its product development targets pet medicines in pain management, anti-allergy and parasiticides that can provide superior convenience and greater compliance than traditional products. The firm is developing Promist, a transmucosal oral mist drug delivery technology for use in companion animals. It is also developing Promist products, including VEL504 for pain management and VEL502 for treating allergic atopic dermatitis in canines. The company was founded ion February 18, 2010 and is headquartered in Yardley, PA. | Direktor/Vorstandsmitglied | - |
Ausbildung von Jason Stein
| University of Michigan | Undergraduate Degree |
| Saba University School of Medicine BV | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 7 |
|---|---|
| Ivory Capital Corp. | Finance |
Chelsea Therapeutics International Ltd.
 Chelsea Therapeutics International Ltd. BiotechnologyHealth Technology Chelsea Therapeutics International Ltd. acquires, develops and commercializes innovative products for the treatment of a variety of human diseases. The company was founded by Simon C. Pedder on June 17, 2005 and is headquartered in Charlotte, NC. | Health Technology |
Cutanea Life Sciences, Inc.
Cutanea Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology Cutanea Life Sciences, Inc. Develops and commercialises innovative dermatology related products. The company was founded in May 2005 and is headquartered in Wayne, PA. | Health Technology |
Foresight Biotherapeutics, Inc.
Foresight Biotherapeutics, Inc. BiotechnologyHealth Technology Foresight Biotherapeutics, Inc. develops drugs and therapies for diseases of the eyes and ears. It offers FST-100 (topical ophthalmic drops combining povidone iodine and dexamethasone), a therapy in late-stage development for the treatment of infectious conjunctivitis, an ocular surface condition commonly referred to as pink eye. The company was founded by Jason Stein and Michael Weiser on September 4, 2008 and is headquartered in New York, NY. | Health Technology |
Actin Biomed LLC
Actin Biomed LLC Investment ManagersFinance Founded in 2006 by Michael Weiser and Jason Stein, Actin Biomed LLC is a venture capital firm located in New York City. | Finance |
| Actin Capital LLC | |
Velcera LLC
Velcera LLC Pharmaceuticals: MajorHealth Technology Velcera LLC operates as a pharmaceutical company. It focuses on innovation in the expanding pet health market and its product development targets pet medicines in pain management, anti-allergy and parasiticides that can provide superior convenience and greater compliance than traditional products. The firm is developing Promist, a transmucosal oral mist drug delivery technology for use in companion animals. It is also developing Promist products, including VEL504 for pain management and VEL502 for treating allergic atopic dermatitis in canines. The company was founded ion February 18, 2010 and is headquartered in Yardley, PA. | Health Technology |
